Group 1 - The core point of the article highlights the significant acquisition by Pfizer of Metsera for approximately $9.2 billion, which includes key assets MET-097i and MET-233i [1] - The article mentions that Eli Lilly and Novo Nordisk are also actively developing long-acting platforms, with strategic collaborations established with Camurus and Ascendis by 2025 to utilize their FluidCrystal and TransCon subcutaneous depot technologies for developing long-acting weight loss and glucose-lowering products [1] - Open Source Securities reports that as more clinical data is disclosed, the value of long-acting pipelines and technology platforms will become increasingly evident, predicting that new long-acting therapies will represent the most differentiated competitive direction in the weight loss and glucose-lowering market [1] Group 2 - The article notes that various technologies such as antibody-drug conjugates, fatty acid end-group modifications, and subcutaneous depot controlled-release can achieve long-acting administration, with Singularity Pharmaceuticals having developed multiple long-acting weight loss drug pipelines using its subcutaneous depot ULAP technology platform [1]

Core Viewpoint - Pfizer has successfully completed the acquisition of Metsera for approximately $9.2 billion, gaining access to key assets MET-097i and MET-233i, indicating a strategic move in the long-acting weight loss and diabetes treatment market [1] Company Developments - The stock price of Gilead Sciences-B (01672) has increased by 6.25%, reaching HKD 14.46, with a trading volume of HKD 39.59 million [1] - Gilead has developed a subcutaneous reservoir technology platform (ULAP) for long-acting weight loss drugs, positioning itself in the competitive landscape of obesity and diabetes treatments [1] Industry Trends - Eli Lilly and Novo Nordisk are also actively pursuing long-acting platforms, having formed strategic partnerships with Camurus and Ascendis to develop long-acting weight loss and diabetes products by 2025 [1] - Open Source Securities predicts that the value of long-acting pipelines and technology platforms will become more apparent as clinical data is disclosed, suggesting that long-acting therapies will be a key differentiator in the weight loss and diabetes treatment market [1] - Various technologies such as antibody-drug conjugates, fatty acid end-modification, and subcutaneous reservoir sustained-release methods are expected to enable long-acting drug delivery [1]